{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:36:42Z","timestamp":1790620602279,"version":"4.1.0"},"reference-count":55,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Ricerca Cancro","doi-asserted-by":"crossref","award":["Investigator Grant, IG2020 \u2013 ID.24397"],"award-info":[{"award-number":["Investigator Grant, IG2020 \u2013 ID.24397"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009057","name":"Associazione Italiana per la Lotta al Neuroblastoma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health, Ricerca Corrente","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Italian Ministry of Health, Ricerca Finalizzata 5per mille","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,8,27]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>B7-H3 is a potential target for pediatric cancers, including neuroblastoma (NB). Vobramitamab duocarmazine (also referred to as MGC018 and herein referred to as vobra duo) is an investigational duocarmycin-based antibody-drug conjugate (ADC) directed against the B7-H3 antigen. It is composed of an anti-B7-H3 humanized IgG1\/kappa monoclonal antibody chemically conjugated through a cleavable valine-citrulline linker to a <jats:underline>du<\/jats:underline>ocarmycin-hydroxy<jats:underline>b<\/jats:underline>enzamide <jats:underline>a<\/jats:underline>zaindole (vc-seco-DUBA). Vobra duo has shown preliminary clinical activity in B7-H3-expressing tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>B7-H3 expression was evaluated by flow-cytometry in a panel of human NB cell lines. Cytotoxicity was evaluated in monolayer and in multicellular tumor spheroid (MCTS) models by the water-soluble tetrazolium salt,MTS, proliferation assay and Cell Titer Glo 3D cell viability assay, respectively. Apoptotic cell death was investigated by annexin V staining. Orthotopic, pseudometastatic, and resected mouse NB models were developed to mimic disease conditions related to primary tumor growth, metastases, and circulating tumor cells with minimal residual disease, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All human NB cell lines expressed cell surface B7-H3 in a unimodal fashion. Vobra duo was cytotoxic in a dose-dependent and time-dependent manner against all cell lines (IC50 range 5.1\u201353.9\u2009ng\/mL) and NB MCTS (IC50 range 17.8\u2013364\u2009ng\/mL). Vobra duo was inactive against a murine NB cell line (NX-S2) that did not express human B7-H3; however, NX-S2 cells were killed in the presence of vobra duo when co-cultured with human B7-H3-expressing cells, demonstrating bystander activity. In orthotopic and pseudometastatic mouse models, weekly intravenous treatments with 1\u2009mg\/kg vobra duo for 3 weeks delayed tumor growth compared with animals treated with an irrelevant (anti-CD20) duocarmycin-ADC. Vobra duo treatment for 4 weeks further increased survival in both orthotopic and resected NB models. Vobra duo compared favorably to TOpotecan-TEMozolomide (TOTEM), the standard-of-care therapy for NB relapsed disease, with tumor relapse delayed or arrested by two or three repeated 4-week vobra duo treatments, respectively. Further increased survival was observed in mice treated with vobra duo in combination with TOTEM. Vobra duo treatment was not associated with body weight loss, hematological toxicity, or clinical chemistry abnormalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models and represents a potential candidate for clinical translation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007174","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:20:40Z","timestamp":1695946840000},"page":"e007174","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma"],"prefix":"10.1136","volume":"11","author":[{"given":"Chiara","family":"Brignole","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Calarco","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bensa","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Giusto","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Perri","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ciampi","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Valeria","family":"Corrias","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Astigiano","sequence":"additional","affiliation":[{"name":"Animal Facility, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cilli","sequence":"additional","affiliation":[{"name":"Animal Facility, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derik","family":"Loo","sequence":"additional","affiliation":[{"name":"MacroGenics Inc, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Bonvini","sequence":"additional","affiliation":[{"name":"MacroGenics Inc, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-808X","authenticated-orcid":false,"given":"Fabio","family":"Pastorino","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4286","authenticated-orcid":false,"given":"Mirco","family":"Ponzoni","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2025100309490748000_11.9.e007174.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804577"},{"key":"2025100309490748000_11.9.e007174.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1014"},{"key":"2025100309490748000_11.9.e007174.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-018-2821-2"},{"key":"2025100309490748000_11.9.e007174.4","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025100309490748000_11.9.e007174.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.6785"},{"key":"2025100309490748000_11.9.e007174.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405025101"},{"key":"2025100309490748000_11.9.e007174.7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2025100309490748000_11.9.e007174.8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tranon.2019.11.006","article-title":"B7-H3 as a Prognostic biomarker and therapeutic target in pediatric central nervous system tumors","volume":"13","author":"Maachani","year":"2020","journal-title":"Transl Oncol"},{"key":"2025100309490748000_11.9.e007174.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0432"},{"key":"2025100309490748000_11.9.e007174.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03070.x"},{"key":"2025100309490748000_11.9.e007174.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1030"},{"key":"2025100309490748000_11.9.e007174.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805458105"},{"key":"2025100309490748000_11.9.e007174.13","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.114"},{"key":"2025100309490748000_11.9.e007174.14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/OTT.S63424","article-title":"B7-H3 expression in breast cancer and upregulation of VEGF through gene silence","volume":"7","author":"Sun","year":"2014","journal-title":"OTT"},{"key":"2025100309490748000_11.9.e007174.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709802104"},{"key":"2025100309490748000_11.9.e007174.16","doi-asserted-by":"publisher","DOI":"10.1179\/1607845414Y.0000000186"},{"key":"2025100309490748000_11.9.e007174.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3107"},{"key":"2025100309490748000_11.9.e007174.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108153","article-title":"The role of B7-H3 in tumors and its potential in clinical application","volume":"101","author":"Feng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2025100309490748000_11.9.e007174.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2584"},{"key":"2025100309490748000_11.9.e007174.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268"},{"key":"2025100309490748000_11.9.e007174.21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2025100309490748000_11.9.e007174.22","doi-asserted-by":"crossref","unstructured":"Dan N , Setua S , Kashyap V , et al . n.d. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals;11:32. doi:10.3390\/ph11020032","DOI":"10.3390\/ph11020032"},{"key":"2025100309490748000_11.9.e007174.23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody-drug conjugates","volume":"20","author":"do Pazo","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2025100309490748000_11.9.e007174.24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116"},{"key":"2025100309490748000_11.9.e007174.25","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1200\/JCO.2021.39.15_suppl.10037","article-title":"Testing of B7-H3 targeting antibody-drug conjugate (ADC) Mgc018 in models of pediatric solid tumors by the pediatric Preclinical testing consortium (PPTC)","volume":"39","author":"Kurmasheva","year":"2021","journal-title":"JCO"},{"key":"2025100309490748000_11.9.e007174.26","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","article-title":"Phase 1 dose escalation study of Mgc018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"39","author":"Jang","year":"2021","journal-title":"JCO"},{"key":"2025100309490748000_11.9.e007174.27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.biomaterials.2015.07.054","article-title":"Neuroblastoma-targeted Nanocarriers improve drug delivery and penetration, delay tumor growth and Abrogate metastatic diffusion","volume":"68","author":"Cossu","year":"2015","journal-title":"Biomaterials"},{"key":"2025100309490748000_11.9.e007174.28","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201906426","article-title":"Combined replenishment of miR-34A and Let-7B by targeted nanoparticles inhibits tumor growth in neuroblastoma Preclinical models","volume":"16","author":"Di Paolo","year":"2020","journal-title":"Small"},{"key":"2025100309490748000_11.9.e007174.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0804"},{"key":"2025100309490748000_11.9.e007174.30","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201802886","article-title":"Enhancement of tumor homing by chemotherapy-loaded nanoparticles","volume":"14","author":"Ponzoni","year":"2018","journal-title":"Small"},{"key":"2025100309490748000_11.9.e007174.31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.21.1586"},{"key":"2025100309490748000_11.9.e007174.32","first-page":"1300","article-title":"Surface Igm-Kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines","volume":"28","author":"Klein","year":"1968","journal-title":"Cancer Res"},{"key":"2025100309490748000_11.9.e007174.33","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072178","article-title":"The olive leaves extract has anti-tumor effects against neuroblastoma through inhibition of cell proliferation and induction of apoptosis","volume":"13","author":"Morandi","year":"2021","journal-title":"Nutrients"},{"key":"2025100309490748000_11.9.e007174.34","doi-asserted-by":"crossref","unstructured":"Brignole C , Bensa V , Fonseca NA , et al . Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. J Exp Clin Cancer Res 2021;40. doi:10.1186\/s13046-021-01993-9","DOI":"10.1186\/s13046-021-01993-9"},{"key":"2025100309490748000_11.9.e007174.35","first-page":"7400","article-title":"Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy","volume":"63","author":"Pastorino","year":"2003","journal-title":"Cancer Res"},{"key":"2025100309490748000_11.9.e007174.36","doi-asserted-by":"publisher","DOI":"10.2174\/092986707782793916"},{"key":"2025100309490748000_11.9.e007174.37","first-page":"86","article-title":"Doxorubicin-loaded Fab' fragments of anti-Disialoganglioside Immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice","volume":"63","author":"Pastorino","year":"2003","journal-title":"Cancer Res"},{"key":"2025100309490748000_11.9.e007174.38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102989","article-title":"Targeting vesicular Lgals3Bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma","volume":"12","author":"Capone","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100309490748000_11.9.e007174.39","doi-asserted-by":"crossref","unstructured":"Corallo D , Pastorino F , Pantile M , et al . Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor Ponatinib. J Exp Clin Cancer Res 2020;39. doi:10.1186\/s13046-020-01692-x","DOI":"10.1186\/s13046-020-01692-x"},{"key":"2025100309490748000_11.9.e007174.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1354"},{"key":"2025100309490748000_11.9.e007174.41","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1002\/ijc.32058","article-title":"Preclinical evaluation of the first intravenous small molecule Mdm2 antagonist alone and in combination with Temozolomide in neuroblastoma","volume":"144","author":"Chen","year":"2019","journal-title":"Int J Cancer"},{"key":"2025100309490748000_11.9.e007174.42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2020.11.014","article-title":"The immune landscape of neuroblastoma: challenges and opportunities for novel therapeutic strategies in pediatric oncology","volume":"144","author":"Wienke","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100309490748000_11.9.e007174.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00643-z"},{"key":"2025100309490748000_11.9.e007174.44","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00947-7","article-title":"\u201cAntibody drug conjugate: the \"biological missile\" for targeted cancer therapy\u201d","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025100309490748000_11.9.e007174.45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004646","article-title":"Therapeutic efficacy of antibody-drug conjugates targeting Gd2-positive tumors","volume":"10","author":"Kalinovsky","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100309490748000_11.9.e007174.46","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100344","article-title":"A Gpc2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational EPITOPE","volume":"2","author":"Raman","year":"2021","journal-title":"Cell Rep Med"},{"key":"2025100309490748000_11.9.e007174.47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau9732","article-title":"An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in Preclinical models of neuroblastoma","volume":"11","author":"Sano","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100309490748000_11.9.e007174.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4221"},{"key":"2025100309490748000_11.9.e007174.49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002293","article-title":"Multiparametric flow Cytometry highlights B7-H3 as a novel diagnostic\/therapeutic target in Gd2Neg\/low neuroblastoma variants","volume":"9","author":"Dondero","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100309490748000_11.9.e007174.50","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24683"},{"key":"2025100309490748000_11.9.e007174.51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68324-4","article-title":"Characterization of Multicellular breast tumor Spheroids using image data-driven biophysical mathematical modeling","volume":"10","author":"Bowers","year":"2020","journal-title":"Sci Rep"},{"key":"2025100309490748000_11.9.e007174.52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1572"},{"key":"2025100309490748000_11.9.e007174.53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30355-8"},{"key":"2025100309490748000_11.9.e007174.54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2013.08.012","article-title":"Phase II study of Temozolomide in combination with Topotecan (TOTEM) in Relapsed or refractory neuroblastoma: a European innovative therapies for children with cancer-SIOP-European neuroblastoma study","volume":"50","author":"Di Giannatale","year":"2014","journal-title":"European Journal of Cancer"},{"key":"2025100309490748000_11.9.e007174.55","doi-asserted-by":"crossref","unstructured":"Le Teuff G , Castaneda\u2010Heredia A , Dufour C , et al . Phase II study of Temozolomide and Topotecan (TOTEM) in children with Relapsed or refractory Extracranial and central nervous system tumors including Medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Pediatric Blood & Cancer 2020;67. doi:10.1002\/pbc.28032 Available: https:\/\/onlinelibrary.wiley.com\/toc\/15455017\/67\/1","DOI":"10.1002\/pbc.28032"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:49:17Z","timestamp":1759510157000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jitc-2023-007174"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007174","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}